The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

NCT03384511 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Malignancies
Stomach Cancer
Non-small Cell Lung Cancer
Esophageal Cancer
Breast Cancer
Ovary Cancer
Cervical Cancer

Interventions

DRUG: Apatinib

Sponsor

Shandong Cancer Hospital and Institute